BioResources
12 Funding Rounds That Show Where APAC Biotech Capital Is Going
There is a version of this story that lists twelve press releases and calls it analysis. This is not that story. Every round below has already been announc...
July 30, 2026 | News
How Is Connected Care Reaching Patients at Home?
At the edge of this trend sit simple connected safety devices that keep patients linked to help. To see how that works in practice, learn more about home e...
July 27, 2026 | News
7 Countries Competing to Be the Region’s Next Biomanufacturing Hub
A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...
July 27, 2026 | Analysis
The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028
There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...
July 24, 2026 | Analysis
The Technology Is Ready. Are APAC’s Regulators?
In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...
July 15, 2026 | Regulatory
Innovations in Hematologic Oncology: Addressing Unmet Needs in CLL Care
Lymphocyte Type, Blood Cancer Chronic lymphocytic leukaemia (CLL) is a blood malignancy caused by an overproduction of lymphocytes in the blood, lymphatic...
July 13, 2026 | Analysis
Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...
July 14, 2026 | Analysis
The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...
July 13, 2026 | Analysis
Can APAC Build Radioligand Therapy Before the Atoms Decay?
Every dose of radioligand therapy is a countdown. The moment a batch of lutetium-177 leaves the reactor, it begins to fade — roughly half its therape...
July 02, 2026 | Analysis
Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site
Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...
July 01, 2026 | News
The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...
June 30, 2026 | Analysis
Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
A new medicine arrives at a regulator's desk with two kinds of proof attached. The first is the familiar kind: a randomised controlled trial, blinded, cont...
June 30, 2026 | Analysis
Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...
June 29, 2026 | Analysis
Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires
For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...
June 25, 2026 | Analysis
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
